WIM INVESTMENT MANAGEMENT Ltd Makes New Investment in ASP Isotopes Inc. $ASPI

WIM INVESTMENT MANAGEMENT Ltd bought a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) during the fourth quarter, HoldingsChannel.com reports. The firm bought 601,400 shares of the company’s stock, valued at approximately $3,217,000. ASP Isotopes accounts for approximately 0.8% of WIM INVESTMENT MANAGEMENT Ltd’s holdings, making the stock its 16th biggest holding.

Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in ASP Isotopes during the third quarter worth $34,000. BNP Paribas Financial Markets raised its holdings in shares of ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares during the last quarter. Close Asset Management Ltd acquired a new position in shares of ASP Isotopes in the third quarter worth $72,000. Legal & General Group Plc raised its holdings in shares of ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after acquiring an additional 1,953 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of ASP Isotopes by 96.7% in the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares during the last quarter. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ASP Isotopes

In related news, Director Duncan Moore sold 11,642 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total value of $60,654.82. Following the completion of the transaction, the director directly owned 1,044,928 shares in the company, valued at approximately $5,444,074.88. This represents a 1.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Robert Ainscow sold 25,000 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $4.51, for a total value of $112,750.00. Following the completion of the transaction, the chief operating officer owned 1,512,817 shares of the company’s stock, valued at $6,822,804.67. The trade was a 1.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 90,704 shares of company stock worth $463,252. 14.40% of the stock is currently owned by insiders.

ASP Isotopes Stock Performance

ASP Isotopes stock opened at $6.32 on Thursday. The firm has a market capitalization of $795.69 million, a P/E ratio of -2.95 and a beta of 3.26. The stock has a fifty day moving average price of $5.08 and a 200 day moving average price of $6.16. ASP Isotopes Inc. has a 52 week low of $3.92 and a 52 week high of $14.49. The company has a current ratio of 12.23, a quick ratio of 12.20 and a debt-to-equity ratio of 0.77.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Friday, April 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.70). The business had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 161.55%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price target on shares of ASP Isotopes in a report on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ASP Isotopes currently has a consensus rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.